Scholarlink

Purpose <p>In the postMONARCH trial, abemaciclib plus fulvestrant (FUL) yielded a progression-free survival (PFS) of 6.0 months in hormone receptor (HR)-positive HER2-negative metastatic breast cancer patients who progressed after receiving CDK4/6 inhibitor plus endocrine therapy (ET). However, only 8% of these patients had previously received abemaciclib.</p> Methods <p>This multicenter, single-arm, phase II study enrolled patients who developed disease progression after abemaciclib plus ET. Patients were switched from aromatase inhibitor (AI)/tamoxifen (TAM) to FUL or from FUL to AI while continuing abemaciclib. The primary endpoint was PFS. The secondary endpoints were the overall response rate (ORR), clinical benefit rate (CBR), chemotherapy-free interval (CFI), overall survival (OS), and safety. Biomarker analysis was performed based on gene alterations.</p> Results <p>This study enrolled 65 patients from June 2021 to November 2023; 64 patients could be evaluated following 1 withdrawal. The median PFS for the 64 patients was 4.2 months (90% CI, 2.8–4.4). The median PFS was 7.1 months (95% CI, 3.9–11.3) in patients who switched from abemaciclib plus AI/TAM to abemaciclib plus FUL (<i>n</i> = 28, 43.8%), whereas it was 2.8 months (95% CI, 1.9–4.2) in patients switching from abemaciclib plus FUL to abemaciclib plus AI (<i>n</i> = 36, 56.3%). The ORR was 8.7% (95% CI, 2.4–20.8), the CBR was 23.9% (95% CI, 12.6–38.8), the CFI was 6.7 months (95% CI, 4.9–11.0), and the OS was 28.7 months (95% CI, 25.4–not estimable [NE]).</p> Conclusions <p>The primary endpoint was not met; switching from abemaciclib plus AI/TAM to abemaciclib plus FUL may be a clinically effective option.</p> jRCTs031210129 <p>Date of registration JUNE 2, 2021.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Meiko Nishimura,
  • Takahiro Kogawa,
  • Keiji Sugiyama,
  • Yukinori Ozaki,
  • Yuko Tanabe,
  • Chikako Funasaka,
  • Sasagu Kurozumi,
  • Akiyo Yoshimura,
  • Tsutomu Iwasa,
  • Hitomi Sakai,
  • Mitsunori Morita,
  • Satomi Watanabe,
  • Takaaki Fujii,
  • Mitsugu Yamamoto,
  • Yasushi Tsuji,
  • Mitsuo Terada,
  • Takayo Ota,
  • Shinya Tokunaga,
  • Mototsugu Shimokawa,
  • Toshimi Takano

摘要

Purpose

In the postMONARCH trial, abemaciclib plus fulvestrant (FUL) yielded a progression-free survival (PFS) of 6.0 months in hormone receptor (HR)-positive HER2-negative metastatic breast cancer patients who progressed after receiving CDK4/6 inhibitor plus endocrine therapy (ET). However, only 8% of these patients had previously received abemaciclib.

Methods

This multicenter, single-arm, phase II study enrolled patients who developed disease progression after abemaciclib plus ET. Patients were switched from aromatase inhibitor (AI)/tamoxifen (TAM) to FUL or from FUL to AI while continuing abemaciclib. The primary endpoint was PFS. The secondary endpoints were the overall response rate (ORR), clinical benefit rate (CBR), chemotherapy-free interval (CFI), overall survival (OS), and safety. Biomarker analysis was performed based on gene alterations.

Results

This study enrolled 65 patients from June 2021 to November 2023; 64 patients could be evaluated following 1 withdrawal. The median PFS for the 64 patients was 4.2 months (90% CI, 2.8–4.4). The median PFS was 7.1 months (95% CI, 3.9–11.3) in patients who switched from abemaciclib plus AI/TAM to abemaciclib plus FUL (n = 28, 43.8%), whereas it was 2.8 months (95% CI, 1.9–4.2) in patients switching from abemaciclib plus FUL to abemaciclib plus AI (n = 36, 56.3%). The ORR was 8.7% (95% CI, 2.4–20.8), the CBR was 23.9% (95% CI, 12.6–38.8), the CFI was 6.7 months (95% CI, 4.9–11.0), and the OS was 28.7 months (95% CI, 25.4–not estimable [NE]).

Conclusions

The primary endpoint was not met; switching from abemaciclib plus AI/TAM to abemaciclib plus FUL may be a clinically effective option.

jRCTs031210129

Date of registration JUNE 2, 2021.